Healthcare
Poly Medicure Limited (POLYMED) breaks out, gains 5% intraday
Poly Medicure Limited (NSE: POLYMED) stock breaks out, clearing its 6M resistance trendline and gaining 5% intraday to ₹1875.1.
Poly Medicure Limited (POLYMED) breaks out with a +5% gain to ₹1875.1 on the NSE on 11 Aug 2026, clearing its 6-month resistance trendline after a period of breakdown. This move comes as the company informed the Exchange about the recording of an Analysts/Institutional Investor Meet/Con. Call and a Monitoring Agency Report for the quarter ended 30th June, 2026. Poly Medicure, a key player in the healthcare sector specializing in medical instruments and supplies, has shown a company-specific surge, outperforming broader sector trends which have been mixed.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows a breakout above the resistance trendline at ₹1682.64, with the stock now trading 10.26% above this level. The 6-month support trendline is at ₹1792.4, which is 4.41% below today’s price. The 50-DMA at ₹1610.5 is above the 200-DMA at ₹1587.9, indicating a bullish trend, though the stock is currently extended, trading 10.05% above the 50-DMA. Within its 52-week range of ₹1182.0 to ₹2144.9, the stock is in the upper third, suggesting that a substantial portion of the potential upside may already be priced in.
Snapshot: ₹1,875.10 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 56.0, Poly Medicure’s valuation appears stretched given its profit margin of 15.8% and revenue CAGR of 19.0%. This suggests that the market may be pricing in aggressive future growth expectations. Institutional ownership stands at 18.1%, indicating a cautious but present interest from smart money. There is no specific NSE catalyst today driving the move, which suggests the breakout may be more technically driven.
Algorithmic scorecard
The overall algorithmic scorecard of 74 reflects a balanced view, with strong technical indicators offset by some fundamental concerns. The strongest signals include the bullish trend, with the 50-DMA above the 200-DMA, and the very low debt levels, indicated by a D/E ratio of 0.07, which points to excellent financial health. On the flip side, the weakest signals are the overvalued PEG ratio of 2.95, suggesting the stock is expensive relative to its growth rate, and the negligible dividend yield of 0.21%, offering little income to shareholders. These factors highlight the need for cautious optimism, balancing the technical breakout with an awareness of the valuation risks.
Company outlook
Poly Medicure has guided for a revenue of INR2,300 crores to INR2,400 crores for FY ’27 on a consolidated basis, up from INR1,875 crores in FY ’26. On a stand-alone basis, the company expects revenue between INR1,900 crores and INR1,950 crores for FY ’27, with domestic business growing upwards of 20% and international business growing upwards of 15%. The stand-alone EBITDA margin is expected to be in the range of 25% to 27%, while the consolidated EBITDA margin is expected to be between 23% and 25%. The company anticipates a 20% growth in the Renal segment and low double-digit growth for Citieffe in euro terms for FY ’27. Additionally, Poly Medicure plans to spend between INR200 crores to INR225 crores on capex this year, focusing on automation to mitigate wage revisions, and is working on synergies and engineering work in India to improve the margins of recently acquired companies, Citieffe and PendraCare.
Get all details on POLYMED — P&L, peers, shareholding and more on TradeAlone.
Healthcare
Jagsonpal Pharmaceuticals Limited Acquires Wellness Portfolio of Group Pharmaceuticals
Jagsonpal Pharmaceuticals Ltd. acquires Wellness Portfolio of Group Pharmaceuticals, enhancing its pharmaceutical portfolio and market reach.
Jagsonpal Pharmaceuticals Limited (Jagsonpal) today announced the execution of a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited (Group Pharma) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves an initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of up to ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of conditions precedent and other terms stipulated under the BTA.
Strategic Growth Move
This acquisition marks another meaningful step in Jagsonpal’s growth journey. It strengthens the company’s pharmaceutical portfolio and expands its presence across complementary therapeutic segments, especially in women healthcare, while remaining consistent with its asset-light and focused approach to growth. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: ‘The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.’
Seamless Integration
Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: ‘We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.’
The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA. Think Law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Jagsonpal posts a 0.9% three-month gain, but softens in the last few weeks. The PEG of 1.95 limits the upside. The stock does not come cheap. Revenue grows at 6.7% and profits at 17.3% CAGR. The numbers are respectable but unlikely to re-rate the stock. The stock gives back 3.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 0.9% in three months on 6.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Jagsonpal Pharmaceuticals Limited.
Health Information Services
Indegene Limited (indgn): from Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI
Indegene Limited (INDGN) highlights at Digital Summit 2026: Leaders focus on operationalizing AI for enterprise outcomes.
Indegene Limited (INDGN) recently hosted its eighth edition of the Digital Summit, focusing on operationalizing AI to deliver enterprise outcomes in the life sciences sector. The event, held on September 22 at the National Constitution Center in Philadelphia, brought together over 200 senior leaders to discuss translating AI investments into measurable business impact.
Operationalizing AI for Business Impact
The summit’s theme, ‘From Promise to Performance: Operationalizing AI for Enterprise Outcomes,’ emphasized the need for a next-generation operating model in life sciences. Speakers highlighted how AI can connect data, intelligence, and evidence to enable strategic decisions, drive successful product launches, and accelerate drug discovery and clinical research.
Recognition at VITAL Awards
The summit also hosted the second edition of the VITAL Awards, recognizing leaders delivering measurable industry impact. Honorees were named in Organizational Impact and Market Impact categories, alongside special awards for Transformational Leadership. Notable recipients included Brian Cantwell and Agam Upadhyay for Transformational Leadership, and Saket Malhotra for Organizational Impact.
Manish Gupta, Chairman and CEO of Indegene, remarked, ‘Life sciences has built an extraordinary legacy of helping people live longer, healthier lives. But increasingly specialized therapies and precision medicines cannot be supported by operating models designed for an era of mass promotion. The opportunity now is to thoughtfully rewire the enterprise around AI, augment our people, and build systems that are smarter, faster, and more responsive, turning the promise of technology into measurable performance for patients, physicians, and the business.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 15.5% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 2.1x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 15.5% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
GLENMARK
Glenmark Pharmaceuticals Limited Receives E Stablishment Inspection Report from U.S. FDA
Glenmark Pharmaceuticals Limited (GLENMARK) receives Establishment Inspection Report from U.S. FDA for its Goa facility with Voluntary Action Indicated status.
Glenmark Pharmaceuticals Limited (GLENMARK) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa, India, with a Voluntary Action Indicated (VAI) status. The inspection was conducted from June 22, 2026, to June 30, 2026. This report is a significant milestone for the company as it underscores the quality and compliance of its manufacturing processes.
Inspection Highlights
The U.S. FDA’s inspection team evaluated various aspects of the manufacturing facility, including production protocols, quality control measures, and overall facility management. Notably, the FDA highlighted areas that require voluntary actions to address certain observations. This VAI classification indicates that while the facility meets most regulatory standards, there are specific areas needing improvement.
Company’s Response
Glenmark Pharmaceuticals Limited is committed to addressing the observations mentioned in the report. The company plans to implement corrective and preventive actions to ensure full compliance with FDA standards. This proactive approach will help Glenmark maintain its reputation for high-quality pharmaceutical manufacturing.
As a result, Glenmark Pharmaceuticals Limited continues to focus on innovation and accessibility, aiming to deliver affordable and high-quality medicines globally. The company’s robust manufacturing infrastructure and commitment to excellence will drive its ongoing success and compliance with international regulatory standards.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Glenmark rises 12.9% over three months, with buying pressure holding steady. The PEG of 0.59 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 13.5% and profits at 66.1% CAGR. The market consistently rewards this kind of compounding. The stock trades at 90% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.59 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.
-
Basic Materials2 days agoEuro Pratik Sales Limited (europratik) to Acquire 56% Stake in Fab Wood, Expanding into Timber and Value-added Wood Products
-
INTELLECT2 days agoIntellect Design Arena Limited Upgrades Cargills Bank’s Core Banking Architecture for the Next Decade
-
Industrials2 days agoOne Point One Solutions Limited Secures INR 39.32 Crore Customer Experience Centre of Excellence Mandate
-
Credit Services3 days agoManba Finance Limited (manba) Approves ₹99.99 Crore Fundraise
-
Basic Materials2 days agoJindal Stainless Partners with Nasscom’s Futureskills Prime to Enhance Workforce Digital Capabilities
-
Communication Services3 days agoPrime Focus Limited Announces Brahma AI Raises $150 Million
-
AWFIS2 days agoAwfis Space Solutions Limited (awfis) Launches New Elite Centre in Aerocity
-
Consumer Cyclical2 days agoRoyal Orchid Hotels Limited Rohltd Expands Presence in Karnataka with Regenta Hubballi Launch